Skip to content

Mark's Value3 Insider - #7

CSL Still a Buy? + Invitation to Next Value3 Q&A

The recent market rally has pushed many high-quality ASX stocks back toward their all-time highs.

Since 7 April, Pro Medicus has surged nearly 60%, now trading around $280—just shy of its record $299. Wisetech is also bouncing back, rising roughly 35% over the same period.

It's natural to wonder: Have I missed the boat?

Not necessarily. One top-tier ASX company is still trading well below its peak—and it may represent a rare opportunity.

That company is CSL.

CSL: Australia's Greatest Healthcare Success Story

Founded in 1916, CSL is one of Australia's most successful global healthcare companies.

It operates through three core units:

  • CSL Behring – blood plasma collection
  • CSL Seqirus – a leading influenza vaccine provider
  • CSL Vifor – treatments for iron deficiency and kidney disease (acquired in 2022)

Despite a long and impressive track record, CSL has struggled in recent years. Its share price is down 17% over the past 5 years, weighed down by underwhelming performance and rising debt.

So... what now?

Is CSL on the Cusp of a New Phase?

CSL remains one of the most widely held companies on the ASX.

Some long-time shareholders are questioning whether it's time to let go. Others are wondering if the current price offers a compelling entry point.

To answer those questions, Bruce Carmichael, our Financial Specialist, recently spoke with CSL's management and has provided our Value 3 financial analysis in the video below.

Video analysis also available on our Media Page.

Why This May Be a Turning Point

Management has acknowledged past mistakes and is making meaningful changes:

  • Laser-focused on controlling costs, especially fixed costs
  • Rethinking R&D to reduce risk and shorten time-to-market
  • Actively exploring partnerships with companies that have promising mid-stage research

This last point could be a game-changer—allowing CSL to:

  • Cut upfront costs
  • Share development risks
  • Broaden its product scope
  • Accelerate time to market

Given the long time horizons in healthcare, CSL requires patience. But for long-term investors, the current price offers potential upside.

👉 According to our PriZone valuation, CSL is attractively priced today.

Join Me for the Next Value3 Webinar & Q&A

I'll be hosting a live session to update you on the companies we've covered—and answer your questions.

Register now

Can't make it? No problem—we'll send the replay to everyone who registers.

Send any questions in advance to hello@value3.com

Disclosure: General advice only. Past performance ≠ future results.